A recent case report describes an elderly woman who was first diagnosed with myasthenia gravis (MG) after experiencing a…
Margarida Maia, PhD
Science Writer
Margarida Maia, PhD, is a science and medical writer with a background in biochemistry and biomedical sciences. She studied in Portugal and Belgium and has been working in science communication for several years. She has been writing at Bionews since 2021. Her work focuses on explaining new research and medical developments on rare diseases in a clear and accessible way.
Education
- PhD in Biomedical Sciences, VIB & KU Leuven, Belgium
- Degree in Biochemistry, University of Porto, Portugal
Certifications
- Google Project Management: Professional Certificate
Published Works
- Valdez, Y, Maia, M, Conway EM. CD248: Reviewing its role in health and disease. Curr Drug Targets. 2012;13:432–439.
- Maia, M et al. CD248 facilitates tumor growth via its cytoplasmic domain. BMC Cancer. 2011;11:162.
- Antunes, R, Brandão, C, Maia, M, Arosa, FA. Red blood cells release factors with growth and survival bioactivities for normal and leukemic T cells. Immunol Cell Biol. 2011;89:111–121.
- Maia, M et al. CD248 and its cytoplasmic domain: A therapeutic target for arthritis. Arthritis Rheum. 2010;62:.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
Zytux, a biosimilar of rituximab, may be effective and safe for patients with hard-to-treat myasthenia gravis (MG), a…
Muscle and physical function improved in patients with clinically stable myasthenia gravis (MG) who participated in an individually tailored…
An elderly man in India developed generalized myasthenia gravis (MG) after contracting COVID-19, but his condition improved after he…
Thymectomy – surgical removal of the thymus gland — may be a better option for treating patients with early-onset non-thymomatous…
A micro RNA molecule called miR-146a was found at high levels in the blood of patients with myasthenia gravis…
Patients with myasthenia gravis (MG) and self-reactive antibodies against the muscle-specific kinase (MuSK) protein are more likely to have…
A new type of plasma exchange treatment, called double-filtration plasmapheresis (DFPP), may be effective and safe for short-term relief of…